The VENTANA PD-L1 (SP142) Assay is the first and only CDx that’s FDA approved to help identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ® (atezolizumab).1,2 You can run this assay on your BenchMark ULTRA system or send it to one of our testing centers.
We value your privacy.
Learn about the tumor microenvironment, PD-L1 expression on immune and tumor cells and the development process for companion diagnostic tests.
Watch our online microscopy training, “Scoring the VENTANA PD-L1 (SP142) Assay for the TNBC indication,” hosted by Roche Medical and Scientific Affairs Pathologists.
Find online training courses for the VENTANA PD-L1 (SP142) Assay. Topics include PD-L1 expression, the tumor microenvironment and information on the other cancer indications.
The VENTANA PD-L1 (SP142) Assay* is the first and only FDA-approved test predictive for TECENTRIQ® (atezolizumab) in urothelial carcinoma (UC) patients. It is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.
*In the US available only on the VENTANA BenchMark ULTRA automated slide staining instrument.
The VENTANA PD-L1 (SP142) Assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ® (atezolizumab).*
*All randomized patients in an NSCLC phase III study observed benefit from TECENTRIQ® (atezolizumab) regardless of PD-L1 status.
